Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Chimeric antigen receptor-T-cellebehandling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jason P Cooper
  • Barry E Storer
  • Noa Granot
  • Boglark Gyurkocza
  • Mohamed L Sorror
  • Thomas R Chauncey
  • Judith Shizuru
  • Georg-Nikolaus Franke
  • Michael B Maris
  • Michael Boyer
  • Benedetto Bruno
  • Firoozeh Sahebi
  • Amelia A Langston
  • Parameswaran Hari
  • Edward D Agura
  • Søren Lykke Petersen
  • Richard T Maziarz
  • Wolfgang Bethge
  • Julie Asch
  • Jonathan A Gutman
  • Gitte Olesen
  • Andrew M Yeager
  • Kai Hübel
  • William J Hogan
  • David G Maloney
  • Marco Mielcarek
  • Paul J Martin
  • Mary E D Flowers
  • George E Georges
  • Ann E Woolfrey
  • H Joachim Deeg
  • Bart L Scott
  • George B McDonald
  • Rainer Storb
  • Brenda M Sandmaier
Vis graf over relationer

We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997-2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation +/- fludarabine or clofarabine before transplantation from HLA-matched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997 +/- 2003 (n=562), 2004 +/- 2009 (n=594), and 2010 +/- 2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997 +/- 2003 to 56% in 2010-2017, and with scores from the Hematopoietic Cell Transplantation Comborbidity Index of ≥3 increased from 25% in 1997 +/- 2003 to 45% in 2010 +/- 2017. Use of unrelated donors increased from 34% in 1997 +/- 2003 to 65% in 2010-2017. When outcomes from 2004 +/- 2009 and 2010-2017 were compared to 1997 +/- 2003, improvements were noted in overall survival (P=.0001 for 2004-2009 and P <.0001 for 2010-2017), profression-free survival (P=.002 for 2004-2009 and P <.0001 for 2010 +/- 2017), non-relapse mortality (P<.0001 for 2004 +/- 2009 and P <.0001 for 2010 +/- 2017), and in rates of grades 2 +/- 4 acute and chronic graft-vs.-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under ClinicalTrials.gov identifiers: NCT00003145, NCT00003196, NCT00003954, NCT00005799, NCT00005801, NCT00005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045.

OriginalsprogEngelsk
TidsskriftHaematologica
Vol/bind106
Udgave nummer6
Sider (fra-til)1599-1607
Antal sider9
ISSN0390-6078
DOI
StatusUdgivet - 1 jun. 2021

Bibliografisk note

Copyright © 2020, Ferrata Storti Foundation.

ID: 62102407